Agios Pharmaceuticals (AGIO) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Strategic vision and progress

• Emphasized a patient-centric approach and deep community engagement to address rare diseases, focusing on transformative medicines and leveraging expertise in cellular metabolism.

• Outlined three chapters of evolution: oncology roots, pivot to rare diseases in 2021, and current expansion phase.

• Achieved all 2024 objectives ahead of schedule, setting up PYRUKYND for multibillion-dollar potential in thalassemia and sickle cell disease.

• Four pillars for future growth: PYRUKYND market expansion, pipeline diversification, experienced team, and strong financials, with $1.7 billion in cash and equivalents as of September 2024.

• 2025 is positioned as a breakout year with priorities on maximizing PYRUKYND, advancing pipeline, and disciplined capital deployment.

PYRUKYND franchise and near-term launches

• PYRUKYND targets thalassemia and sickle cell disease, with regulatory filings in the US, EU, KSA, and UAE; FDA review for thalassemia with PDUFA date set for September 7, 2025, and potential US launch for sickle cell disease in 2026.

• Pivotal phase III studies (ENERGIZE, ENERGIZE-T) for thalassemia met all primary and key secondary endpoints, showing significant improvements in hemoglobin, fatigue, and transfusion burden, with a favorable safety profile.

• The initial US launch of PYRUKYND will target 65% of diagnosed thalassemia patients, supported by established commercial infrastructure and payer education.

• Sickle cell disease phase III RISE UP study completed enrollment in October 2024; topline data expected late 2025, with launch targeted for 2026.

• Commercial strategy focuses on robust education, targeted deployment, and payer engagement.

Pipeline development and innovation

• Advancing tebapivat (AG-946) in low-risk MDS (Phase 2b ongoing, enrollment completion anticipated late 2025) and sickle cell disease (Phase 2 to begin mid-2025).

• Early-stage programs include AG-181 for PKU (Phase 1 ongoing) and AG-236 for polycythemia vera (IND filing mid-2025), both addressing significant unmet needs.

• Orphan drug designation granted for tebapivat in low-risk MDS by FDA.

• Pipeline prioritization is driven by capabilities and resource allocation for maximum value.

• Multiple clinical and regulatory milestones are expected throughout 2025, including pediatric PK deficiency data, thalassemia FDA approval, and pipeline progress.